Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 phase I/IIa study in advanced solid tumors
ChiCTR2000040552Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Nov 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pumitamig in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 1 more (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicity occurrence within 21 days after first administration and Objective response rate. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
pumitamig
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2000040552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040552.